Sugi Predict

Sugi Predict / Compounds / SCHEMBL110927

SCHEMBL110927

SCHEMBL110927

CN1CCN(c2ccccc2CN)CC1

nearest known ligand 0.87

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NCF1 P14598 2/20 0.87
▸ ADRA2C P18825 1/20 0.59
▸ DRD2 P14416 4/20 0.54
▸ DRD3 P35462 4/20 0.54
▸ DRD4 P21917 2/20 0.54
▸ HTR1A P08908 1/20 0.54
▸ HTR2A P28223 1/20 0.54
▸ HTR2C P28335 1/20 0.54
▸ MAPT P10636 2/20 0.45
▸ MAPK1 P28482 2/20 0.45
▸ EGFR P00533 1/20 0.45
▸ LMNA P02545 1/20 0.45
▸ KMT2A Q03164 1/20 0.45
▸ BRD9 Q9H8M2 5/20 0.45
▸ BRPF1 P55201 3/20 0.45
▸ BRD4 O60885 3/20 0.45
▸ BRD7 Q9NPI1 1/20 0.45
▸ HRH2 P25021 1/20 0.43
▸ HRH3 Q9Y5N1 1/20 0.43
▸ KDM4E B2RXH2 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29505669 1.00 NCF1 (0.87) NCF1ADRA2CDRD2DRD3DRD4
SCHEMBL111234 0.93 NCF1 (1.00) NCF1ADRA2CDRD2DRD3DRD4
SCHEMBL27834649 0.90 NCF1 (0.71) NCF1ADRA2CDRD2DRD3DRD4
SCHEMBL3633909 0.86 NCF1 (0.67) NCF1ADRA2CDRD2DRD3DRD4
SCHEMBL8361520 0.85 DRD2 (0.72) NCF1ADRA2CDRD2DRD3DRD4
Hydrochloric Acid SCHEMBL6662186 0.83 NCF1 (0.63) NCF1ADRA2CDRD2DRD3DRD4
SCHEMBL1541501 0.83 NCF1 (0.63) NCF1ADRA2CDRD2DRD3DRD4
SCHEMBL111729 0.82 NCF1 (0.72) NCF1HTR1AMAPTMAPK1EGFR
SCHEMBL16814882 0.82 NCF1 (0.77) NCF1ADRA2CHTR1AMAPTMAPK1
SCHEMBL30607661 0.82 NCF1 (0.62) NCF1DRD2DRD3DRD4HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3364967-B1 FERROPORTIN INHIBITORS VIFOR INT AG (CH) 2026-05-20 — — EP disclosed
US-RE50878-E1 Pyrazolo pyridine derivatives as NADPH oxidase inhibitors CALLIDITAS THERAPEUTICS SUISSE SA (CH) 2026-05-05 — — US disclosed
EP-3365339-B1 NOVEL FERROPORTIN INHIBITORS VIFOR INT AG (CH) 2025-07-16 — — EP disclosed
US-12049461-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections GILEAD SCIENCES, INC. (US) 2024-07-30 — — US disclosed
US-20220363675-A1 Novel Ferroportin Inhibitors VIFOR (INTERNATIONAL) AG (CH) 2022-11-17 — — US disclosed
CN-114668761-A Novel ferroportin inhibitors 威佛（国际）股份公司 2022-06-28 — — CN disclosed
CN-108290878-B Novel ferroportin inhibitors 威佛（国际）股份公司 2022-04-26 — — CN disclosed
US-20210276988-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. 2021-09-09 — — US disclosed
US-11066399-B2 Ferroportin inhibitors VIFOR (INTERNATIONAL) AG (CH) 2021-07-20 — — US disclosed
US-20210139472-A1 Novel Ferroportin Inhibitors VIFOR (INTERNATIONAL) AG (CH) 2021-05-13 — — US disclosed
EP-1863805-A1 PYRIMIDINE COMPOUNDS HAVING TIE2 (TEK) INHIBITORY ACTIVITY AstraZeneca AB (SE) 2007-12-12 — — EP disclosed
US-7291619-B2 Melanocortin receptor agonists ELI LILLY AND COMPANY (US) 2007-11-06 — — US disclosed
WO-2007048066-A2 PYRAZOLO-PYRIMIDINES AS CASEIN KINASE II (CK2) MODULATORS EXELIXIS, INC. (US) 2007-04-26 — — WO disclosed
US-20070049584-A1 Amino-tetrazoles analogues and methods of use ABBVIE INC. 2007-03-01 — — US disclosed
EP-1747206-A1 AMINO-TETRAZOLES ANALOGUES AND METHODS OF USE ABBOTT LABORATORIES (US) 2007-01-31 — — EP disclosed
WO-2006082373-A1 PYRIMIDINE COMPOUNDS HAVING TIES (TEK) INHIBITORY ACTIVITY ASTRAZENECA AB (SE) 2006-08-10 — — WO disclosed
WO-2006048727-A1 PIPERAZINYLPHENALKYL LACTAM/AMINE LIGANDS FOR THE 5HT1B RECEPTOR PFIZER PRODUCTS INC. (US) 2006-05-11 — — WO disclosed
US-20060052374-A1 Amino-tetrazole analogues and methods of use ABBVIE INC. 2006-03-09 — — US disclosed
CN-1241916-C Novel acardite compound, its preparation method and medicinal composition containing said compound SERVIER LAB (FR) 2006-02-15 — — CN disclosed
WO-2005111003-A1 AMINO-TETRAZOLES ANALOGUES AND METHODS OF USE ABBOTT LABORATORIES (US) 2005-11-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210139472-A1 Novel Ferroportin Inhibitors HAMP, SLC40A1, HMOX1 NCF1 1882/4885ADRA2C 1671/4885DRD2 2561/4885
US-12049461-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections NR3C1, NR3C2, NR4A1 NCF1 1648/4885ADRA2C 162/4885DRD2 432/4885
US-11066399-B2 Ferroportin inhibitors HAMP, SLC40A1, FTH1 NCF1 1716/4885ADRA2C 1483/4885DRD2 2761/4885
US-20210276988-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES USEFUL FOR TREATING VIRAL INFECTIONS NR3C1, NR3C2, NR4A1 NCF1 1648/4885ADRA2C 162/4885DRD2 432/4885
US-20070049584-A1 Amino-tetrazoles analogues and methods of use P2RX7, P2RX2, P2RX5 NCF1 2153/4885ADRA2C 146/4885DRD2 1676/4885
US-20060052374-A1 Amino-tetrazole analogues and methods of use P2RX7, P2RX2, P2RX3 NCF1 2200/4885ADRA2C 170/4885DRD2 1803/4885
US-20220363675-A1 Novel Ferroportin Inhibitors HAMP, SLC40A1, HMOX1 NCF1 1882/4885ADRA2C 1671/4885DRD2 2561/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.